LWLei Wei

Lei Wei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lei Wei has a total of 117 co-authors. Here are the top co-authors by number of shared publications:

  • Jing-Wei Zhang

    Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, Hubei, China

    8 shared publications
  • Yihao Tian

    Department of Human Anatomy and Histology and Embryology, School of Basic Medical Sciences, Wuhan University, Wuhan, China

    5 shared publications
  • Kai Li

    Zhang Zhongjing School of Chinese Medicine, Nanyang Institute of Technology Nanyang China

    4 shared publications
  • Meng-Fei Chu

    Department of Human Anatomy, TaiKang Medical School (School of Basic Medical Sciences), Wuhan University Wuhan 430071, Hubei, P. R. China

    4 shared publications
  • Qin Liu

    Department of Pathology and Pathophysiology, Hubei Provincial Key Laboratory of Developmentally Originated Disease, TaiKang Medical School (School of Basic Medical Sciences), Wuhan University Wuhan 430071, Hubei, P. R. China

    4 shared publications
  • Xiao-Ning Yuan

    Department of Pathology and Pathophysiology, Hubei Provincial Key Laboratory of Developmentally Originated Disease, TaiKang Medical School (School of Basic Medical Sciences), Wuhan University Wuhan 430071, Hubei, P. R. China

    4 shared publications

Latest Publications

  • LINC00511 Promotes Breast Cancer Cell Proliferation and Invasion by Mediating MYC-Mediated Regulation of VASP

    by Sirui Huang, Yiqing Xi, Jingbo Gao, Shilong Yu, Le Chen, Yuxia Duan, Zelin Yang, Yu Peng, Lei Wei, Jingwei Zhang


  • IGF2BP2-modified UBE2D1 Interacts with Smad2/3 to Promote the Progression of Breast Cancer: Am J Cancer Res. 2023; 13(7): 2948-2968

    by Xiao-Qing Guan, Xiao-Ning Yuan, Kai-Xiang Feng, You-Cheng Shao, Qin Liu, Ze-Lin Yang, Yan-Yan Chen, Jin Deng, Mei-Shun Hu, Jun Li, et al.

    [This corrects the article on p. 2948 in vol. 13, PMID: 37560007.].

  • Open Access

    Construction of a Nomogram Model for Predicting Pathologic Complete Response in Breast Cancer Neoadjuvant Chemotherapy Based on the Pan-Immune Inflammation Value

    by Zhuowan Tian, Yiqing Xi, Mengting Chen, Meishun Hu, Fangfang Chen, Lei Wei, Jingwei Zhang

    Background: The pan-immune inflammation value (PIV) has unclear predictive utility for pathologic complete response (pCR) in breast cancer patients undergoing neoadjuvant chemotherapy (NAC). This study aimed to evaluate the PIV’s predictive value and develop a nomogram integrating PIV for individualized pCR prediction. Methods: In a retrospective multicenter study of 507 NAC-treated patients (training cohort: 357; validation cohort: 150), independent predictors of pCR were identified through univariate and multivariate logistic regression. A nomogram was constructed and validated using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). Net reclassification improvement (NRI) and integrated discrimination improvement (IDI) evaluated the improvement in performance after incorporating the PIV indicator. Results: The high PIV patients (cutoff: 316.533) had significantly lower pCR rates than the low PIV patients (p < 0.001). The nomogram incorporating PIV, estrogen receptor (ER), human epidermal growth factor receptor-2 (Her2), tumor diameter, clinical node stage, and chemotherapy regimen showed excellent discrimination (training cohort area under the curve (AUC): 0.861, 95% confidence interval (CI): 0.821–0.901; validation cohort AUC: 0.815, 95% CI: 0.748–0.882). The calibration curves demonstrate high prediction accuracy (Hosmer–Lemeshow test: p > 0.05), while DCA, NRI (0.341, 95% CI: 0.181–0.500), and IDI (0.017, 95% CI: 0.004–0.029) confirm clinical utility. Conclusions: The PIV is an independent predictor of pCR, and the PIV-based nomogram provides a reliable tool for optimizing NAC response prediction in breast cancer.


  • Open Access

    METTL3 orchestrates glycolysis by stabilizing the c-Myc/WDR5 complex in triple-negative breast cancer

    by Xiao-Ning Yuan, You-Cheng Shao, Xiao-Qing Guan, Qin Liu, Meng-Fei Chu, Ze-Lin Yang, Hui Li, Sai Zhao, Yi-Hao Tian, Jing-Wei Zhang, et al.


  • Oncogenic BRAF noncanonically promotes tumor metastasis by mediating VASP phosphorylation and filopodia formation

    by Wenting Pan, Yihao Tian, Qian Zheng, Zelin Yang, Yulong Qiang, Zun Zhang, Nan Zhang, Jie Xiong, Xin Zhu, Lei Wei, et al.

    BRAF is frequently mutated in various cancer types and contributes to tumorigenesis and metastasis. As an important switch in RAS signaling pathway, BRAF typically enables the activation of MEK and ERK, and its mutation significantly promotes metastasis. However, whether BRAF could stimulate metastasis via a distinct manner is still unknown. Herein, we found that a portion of the BRAF protein localized at the plasma membrane and that the BRAFV600E mutation led to abundant formation of filopodia, which is a hallmark of invasive cancer cells. Mechanistically, BRAF physically interacts with the pseudopod formation-related protein Vasodilator-stimulated phosphoprotein (VASP), and BRAF specifically catalyzes VASP phosphorylation at Ser157. VASP depletion or disruption of Ser157 phosphorylation preferentially reduced the motility, invasion and metastasis of tumor cells harboring oncogenic BRAF or KRAS. Moreover, in clinical cancer tissues, BRAFV600E was positively correlated with the extent of invasion, and tissues with BRAFV600E expression exhibited elevated levels of VASP Ser157 phosphorylation. Our study therefor reveals a noncanonical mechanism by which oncogenic BRAF or KRAS promotes metastasis, suggests that VASP Ser157 phosphorylation might serve as a valuable therapeutic target in BRAF or KRAS mutant cancers.


  • Open Access

    Oncogenic BRAF noncanonically promotes tumor metastasis by mediating VASP phosphorylation and filopodia formation

    by Feng Li, Wenting Pan, Yihao Tian, Qian Zheng, Zelin Yang, Yulong Qiang, Zun Zhang, Jie Xiong, Xin Zhu, Lei Wei

    BRAF is frequently mutated in various cancer types and contributes to tumorigenesis and metastasis. As an important switch in RAS signalling pathway, BRAF typically enables the activation of MEK and ERK, and its mutation significantly promotes metastasis. However, whether BRAF could stimulate metastasis in a MEK/ERK signalling-independent manner is still unknown. Herein, we found that a portion of the BRAF protein localized at the plasma membrane and that the BRAFV600E mutation led to abundant formation of filopodia, which is a hallmark of invasive cancer cells. Mechanistically, BRAF physically interacts with the pseudopod formation-related protein Vasodilator-stimulated phosphoprotein (VASP), and BRAF specifically catalyzes VASP phosphorylation at Ser157. VASP depletion or disruption of Ser157 phosphorylation preferentially reduced the motility, invasion and metastasis of tumor cells harboring oncogenic BRAF or KRAS. Moreover, in clinical cancer tissues, BRAFV600E was positively correlated with the extent of invasion, and tissues with BRAFV600E expression exhibited elevated levels of VASP Ser157 phosphorylation. Our study therefor reveals a noncanonical mechanism by which oncogenic BRAF or KRAS promotes metastasis, suggests that VASP Ser157 phosphorylation might serve as a valuable therapeutic target in BRAF or KRAS mutant cancers.

    • 1 January 2023
      • Vol. 13  (7) , 3185-3202

    Mettl3 synergistically regulates TGF-β/SMAD2/3 to promote proliferation and metastasis of gastric cancer

    by Xiao-Ning Yuan, Qin Liu, You-Cheng Shao, Xiao-Qing Guan, Ze-Lin Yang, Meng-Fei Chu, Jing-Wei Zhang, Yi-Hao Tian, Lei Wei

    Transforming Growth factor-beta (TGF-beta)/Smad signaling is a complex regulatory network that both inhibits and promotes tumorigenesis. However, the mechanisms underlying the function of TGF-beta/Smad signaling pathway remain to be fully elucidated. As a methyltransferase, METTL3 is closely related to tumor development, but the role of METTL3 in the proliferation and metastasis of TGF-beta/Smad-activated gastric cancer (GC) is unclear. In this study, we identified TGF-beta/Smad2/3 axis as an important carcinogenic pathway in GC, which significantly promoted the proliferation and metastasis of GC. Furthermore, we found that Smad3 mRNA could be modified by m6A, which was subsequently recognized and stabilized by IGF2BP2, thereby enhancing Smad3 protein expression and promoting the activation of TGF-beta/Smad pathway. Importantly, we also found that METTL3 could combine with p-Smad3 to regulate the transcription of downstream target genes. Therefore, this study revealed a novel mechanism by which METTL3 synergistically regulates TGF-beta/Smad2/3 signaling and provide a new potential therapeutic target for the treatment of GC.


    • 1 January 2023
      • Vol. 13  (7) , 2948-+

    IGF2BP2-modified UBE2D1 interacts with Smad2/3 to promote the progression of breast cancer

    by Xiao-Qing Guan, Xiao-Ning Yuan, Kai -Xiang Feng, You-Cheng Shao, Qin Liu, Ze-Lin Yang, Yan-Yan Chen, Jin Deng, Mei-Shun Hu, Jun Li, et al.

    Recent studies have suggested that ubiquitin-conjugating enzyme E2D1 (UBE2D1) is involved in tumor progression. In this study, we found that UBE2D1 expression was upregulated in breast cancer (BC) and was related to the prognosis of BC patients. Through in vitro and in vivo experiments, we demonstrated the aberrant expression of UBE2D1 promoted the proliferation and migration of BC cells, and the IGF2BP2-mediated N6-methyladenosine (m6A) modification increased the stability of UBE2D1 mRNA. Mechanistically, UBE2D1 expression regulated the ac-tivity of TGF-13 signaling through modulating the expression and the phosphorylation level of Smad2/3. Furthermore, UBE2D1 directly bound to Smad2/3 and affected the subsequent binding of Smad2 and Smad3, which is a neces-sary step for TGF-13 signaling activation. Thus, our study reveals a pro-oncogenic role of UBE2D1 in the progression of BC and may provide novel strategies for BC treatment.


  • Open Access

    Clinical outcomes of dialysis patients with COVID-19 in the initial phase of the COVID-19 outbreak in Wuhan, China

    by Xingruo Zeng, Xiaomei Huang, Li Xu, Jianwei Xiao, Lianqing Gu, Yin Wang, Yanhong Tuo, Xun Fang, Wenzhe Wang, Ni Li, et al.

    Purpose Since the end of 2019, dialysis patients have been at risk of coronavirus disease 2019 (COVID-19) as well as other potential complications. Hence, we sought to describe the clinical characteristics of dialysis patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Methods We reviewed clinical outcomes, which consisted of clinical data extracted from the medical records of 695 registered dialysis patients at the Dialysis Center of Central Hospital of Wuhan from January 13th, 2020, to February 29th, 2020, and performed statistical analysis. According to the results, there were 447, 227 and 21 hemodialysis (HD), peritoneal dialysis (PD) and combined HD and PD (HD&PD) cases, respectively. Results During the outbreak of COVID-19, 36 dialysis patients were infected by SARS-CoV-2. Among those 36 patients, 32 (7.2%) were on HD, and 4 (1.8%) were on PD. When comparing SARS-CoV-2 infection between HD and PD, the relative risk was 4.07 (RR = 4.07, 95% CI 1.46–11.35). We noted a median age of 66 years during the observation period, and the number of male patients was 23 (63.9%). There were 15 fatal cases tested positive for SARS-CoV-2 (13 cases on HD and 2 cases on PD). By comparing mortality in the same period of 2018, 2019 and 2020, the all-cause mortality of hemodialysis patients was significantly higher in 2020 (4.89%) than in either 2018 (2.55%) or 2019 (1.97%). There was no significant difference in mortality from all causes excluding COVID-19, during the same period among the 3-year period. However, during the COVID-19 outbreak, the mortality from all causes excluding COVID-19 was 2.73%, which was slightly higher than that from COVID-19 (2.16%). Conclusions Although COVID-19 seriously threatens the health of people with uremia, deaths from all causes excluding COVID-19 during the epidemic cannot be ignored.


  • MAGI2‐AS3 inhibits breast cancer by downregulating DNA methylation of MAGI2

    by Xiaolong Xu, Xiaoning Yuan, Jiali Ni, Jing Guo, Yang Gao, Weinan Yin, Feng Li, Lei Wei, Jingwei Zhang

    Breast cancer is one of the most threatening diseases for women. Long noncoding RNAs were reported to be involved in breast cancer development. In this study, we analyzed The Cancer Genome Atlas breast cancer tissue high‐throughput sequencing data and screened and validated the low‐expressing long noncoding RNA named MAGI2‐AS3. Through gene coexpression analysis, we found that MAGI2‐AS3 has a good expression correlation with MAGI2. Overexpression of MAGI2‐AS3 or MAGI2 in breast cancer cells MCF‐7 would inhibit the Wnt/β‐catenin pathway and inhibit cell proliferation and migration. Gene structure and DNA methylation analysis results indicated that MAGI2‐AS3 may act as a cis‐acting regulatory element downregulating the DNA methylation level of the MAGI2 promoter region, and the DNA demethylase TET1 inhibitor can reverse MAGI2‐AS3 overexpression caused upregulation of MAGI2 and cellular effects. Our findings reveal the role of MAGI2‐AS3 in breast cancer and provide potential novel therapeutic targets for metastatic breast cancer intervention.